Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
16 stopped studies mapped to Carcinosarcoma and descendants · 100% state a reason
Over the 16 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06568172 | Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the… | Phase 3 | suspended | Aug 23, 2024 | National Cancer Institute (NCI) | Other - Other | Other (stated, no rule matched) |
| NCT02874430 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or… | Phase 2 | terminated | Aug 22, 2016 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | study closed early due to slow accrual | Enrollment / accrual |
| NCT02364713 | MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian,… | Phase 2 | terminated | Feb 18, 2015 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT05252416 | (VELA) Study of BLU-222 in Advanced Solid Tumors | Phase 1 | terminated | Feb 23, 2022 | Blueprint Medicines Corporation | This trial was terminated prior to the initiation of Phase 2 for reasons not due to safety concerns. | Safety / toxicity |
| NCT05229601 | A Study of HFB301001 in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | HiFiBiO Therapeutics | The decision to discontinue the trial was made as part of a strategic review of the Sponsor's… | Safety / toxicity |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | withdrawn | May 1, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT04906382 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | Early Phase 1 | terminated | May 28, 2021 | Floor Backes, MD | Sponsor reorganization | Other (stated, no rule matched) |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer… | N/A | terminated | Aug 22, 2018 | University of Washington | Enrollment ended early due to the funding timeline | Enrollment / accrual |
| NCT01367301 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Uterine Cancer | N/A | terminated | Jun 7, 2011 | Albert Einstein College of Medicine | Lack of accrual. PI left the institution | Investigator |
| NCT04688749 | Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage(DermaSense) | — | terminated | Dec 30, 2020 | Aristotle University Of Thessaloniki | Due to COVID-19 | COVID-19 / pandemic |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant… | Phase 1 | terminated | Apr 23, 2019 | Vanderbilt-Ingram Cancer Center | Change in participant landscape and other treatment availability | Other (stated, no rule matched) |
| NCT03933761 | Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or…(PRECISE) | Phase 2 | withdrawn | May 1, 2019 | Australia New Zealand Gynaecological Oncology Group | No eligible patient identified after 18 evaluable patients underwent pre-screening over a 2 year… | Other (stated, no rule matched) |
| NCT03902379 | Web-Based Coping and Communication Skills Intervention in Improving Psychological… | N/A | withdrawn | Apr 4, 2019 | Rutgers, The State University of New Jersey | The study was never initiated, no patients were enrolled. It has been closed with the IRB. | Enrollment / accrual |
| NCT01061606 | Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus | Phase 2 | terminated | Feb 3, 2010 | National Cancer Institute (NCI) | Poor accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials